Free Trial

Blueprint Medicines (BPMC) News Today

Blueprint Medicines logo
$128.12 -0.11 (-0.09%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$128.14 +0.02 (+0.02%)
As of 06/18/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BPMC Latest News

Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Earns Equal Weight Rating from Wells Fargo & Company
Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $129.00 target price (down previously from $143.00) on shares of Blueprint Medicines in a research report on Tuesday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Sees Large Volume Increase - Should You Buy?
Blueprint Medicines (NASDAQ:BPMC) Sees Large Volume Increase - What's Next?
Blueprint Medicines Corporation stock logo
Assenagon Asset Management S.A. Reduces Position in Blueprint Medicines Co. (NASDAQ:BPMC)
Assenagon Asset Management S.A. trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 21.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 76,270 shares of the biotechnology company's stock after
Blueprint Medicines Corporation stock logo
GAMMA Investing LLC Purchases 28,615 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
GAMMA Investing LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11,972.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,854 shares of the biotechnology company's stock after a
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Reaches New 12-Month High - Should You Buy?
Blueprint Medicines (NASDAQ:BPMC) Reaches New 52-Week High - What's Next?
Blueprint Medicines Corporation stock logo
Blueprint Medicines Co. (NASDAQ:BPMC) Stake Raised by Rhumbline Advisers
Rhumbline Advisers grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,933 shares of the biotechnology company'
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Sees Strong Trading Volume - Here's Why
Blueprint Medicines (NASDAQ:BPMC) Sees Strong Trading Volume - Should You Buy?
Blueprint Medicines Corporation stock logo
Best Growth Stocks To Follow Now - June 9th
Blueprint Medicines, Novo Nordisk A/S, Welltower, SpringWorks Therapeutics, Blackstone, BlackRock, and Boston Properties are the seven Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to deliver above-average revenue and ear
Blueprint Medicines Corporation stock logo
NBC Securities Inc. Purchases 2,646 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
NBC Securities Inc. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 132,300.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,648 shares of the biotechnolo
Blueprint Medicines Corporation stock logo
Growth Stocks To Follow Now - June 5th
Blueprint Medicines, Novo Nordisk A/S, BlackRock, Blackstone, and Welltower are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies whose revenues and earnings are expected to grow at an above-average rate relative to the overa
Blueprint Medicines Corporation stock logo
Morgan Stanley Issues Positive Forecast for Blueprint Medicines (NASDAQ:BPMC) Stock Price
Morgan Stanley upped their price objective on Blueprint Medicines from $102.00 to $129.00 and gave the company an "equal weight" rating in a report on Thursday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Given New $129.00 Price Target at UBS Group
UBS Group increased their price target on Blueprint Medicines from $88.00 to $129.00 and gave the company a "neutral" rating in a research report on Thursday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Guggenheim
Guggenheim downgraded shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday.
Blueprint Medicines Corporation stock logo
Promising Mid Cap Stocks To Follow Now - June 3rd
Blueprint Medicines, Direxion Daily TSLA Bull 2X Shares, Oklo, Applied Digital, and D-Wave Quantum are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of publicly traded companies whose market capitalization generally falls between ab
Blueprint Medicines Corporation stock logo
Top Pharmaceutical Stocks To Watch Now - June 3rd
Blueprint Medicines, Eli Lilly and Company, D-Wave Quantum, Merck & Co., Inc., Thermo Fisher Scientific, Regeneron Pharmaceuticals, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded compa
Blueprint Medicines Corporation stock logo
Promising Growth Stocks To Follow Now - June 3rd
Blueprint Medicines, Novo Nordisk A/S, and Incyte are the three Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares in companies whose earnings and revenues are expected to grow at an above-average rate compared to the broader market. These companie
Blueprint Medicines Corporation stock logo
Top Growth Stocks To Follow Now - June 4th
Blueprint Medicines, Novo Nordisk A/S, BlackRock, Venture Global, SpringWorks Therapeutics, Blackstone, and Welltower are the seven Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to increase their earnings and revenues at
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Sees Large Volume Increase - What's Next?
Blueprint Medicines (NASDAQ:BPMC) Sees Strong Trading Volume - Should You Buy?
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Upgraded by Citigroup to "Neutral" Rating
Citigroup raised Blueprint Medicines from a "sell" rating to a "neutral" rating and increased their price target for the stock from $83.00 to $129.00 in a research report on Wednesday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Cut to "Hold" at TD Cowen
TD Cowen cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Citizens Jmp
Citizens Jmp cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of "Hold" by Analysts
Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has been given an average rating of "Hold" by the eighteen brokerages that are covering the stock, Marketbeat.com reports. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rat
Blueprint Medicines Corporation stock logo
Promising Value Stocks To Follow Today - June 2nd
Blueprint Medicines, CoreWeave, Inc. Class A Common Stock, Applied Digital, ProShares UltraPro Short QQQ, and Tempus AI are the five Value stocks to watch today, according to MarketBeat's stock screener tool. Value stocks are shares of companies that appear undervalued by the market relative to the
Blueprint Medicines Corporation stock logo
Mid Cap Stocks To Keep An Eye On - June 2nd
Blueprint Medicines, Applied Digital, and Direxion Daily TSLA Bull 2X Shares are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of publicly traded companies whose total market capitalization generally falls between about $2 billion
Blueprint Medicines Corporation stock logo
Pharmaceutical Stocks To Consider - June 2nd
Blueprint Medicines, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Gilead Sciences, D-Wave Quantum, and Johnson & Johnson are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of companies tha
Blueprint Medicines Corporation stock logo
Top Medical Stocks To Research - June 2nd
Blueprint Medicines, UnitedHealth Group, and Tempus AI are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector—this includes pharmaceutical manufacturers, biotechnology firm
Blueprint Medicines Corporation stock logo
Promising Growth Stocks To Follow Today - June 2nd
Blueprint Medicines, Novo Nordisk A/S, and Basel Medical Group are the three Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to grow their revenues and earnings at above-average rates, often reinvesting profits into expansi
Blueprint Medicines Corporation stock logo
Blueprint Medicines' (BPMC) Sector Perform Rating Reiterated at Scotiabank
Scotiabank reissued a "sector perform" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Monday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Earns "Neutral" Rating from JPMorgan Chase & Co.
JPMorgan Chase & Co. reissued a "neutral" rating and issued a $129.00 target price (down from $130.00) on shares of Blueprint Medicines in a report on Monday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Still a Buy?
Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Should You Buy?
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Given "Market Perform" Rating at JMP Securities
JMP Securities reissued a "market perform" rating on shares of Blueprint Medicines in a research report on Tuesday.
Blueprint Medicines Corporation stock logo
Stephens Reiterates "Equal Weight" Rating for Blueprint Medicines (NASDAQ:BPMC)
Stephens reaffirmed an "equal weight" rating and set a $135.00 price target (down from $150.00) on shares of Blueprint Medicines in a report on Tuesday.
Blueprint Medicines Corporation stock logo
Wolfe Research Reaffirms Peer Perform Rating for Blueprint Medicines (NASDAQ:BPMC)
Wolfe Research reaffirmed a "peer perform" rating on shares of Blueprint Medicines in a research note on Tuesday.
Blueprint Medicines Corporation stock logo
Blueprint Medicines (NASDAQ:BPMC) Reaches New 1-Year High - Here's Why
Blueprint Medicines (NASDAQ:BPMC) Sets New 52-Week High - Here's Why
Blueprint Medicines Corporation stock logo
California State Teachers Retirement System Increases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
California State Teachers Retirement System lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 4.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,259 shares of the biotechnology company's
Get Blueprint Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

BPMC Media Mentions By Week

BPMC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BPMC
News Sentiment

0.50

0.69

Average
Medical
News Sentiment

BPMC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BPMC Articles
This Week

7

9

BPMC Articles
Average Week

Get Blueprint Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BPMC) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners